Clinical trials: Peripheral T Cell Lymphoma (PTCL)
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Lymphoma, Non-Hodgkin Lymphoma
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in…
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
- Trial name
- PRIMAVERA (NCT06137144)
- Testing
- AZD3470, Pembrolizumab
- Where
- 38 sites in United States, Australia and 9 more
- Volunteers
- 161 people
- Sponsor
- AstraZeneca
T-cell NHL (PTCL or CTCL)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
- Trial name
- NCT07192471
- Testing
- KK2223
- Where
- 22 sites in United States, Italy and 1 more
- Volunteers
- 72 people
- Sponsor
- Kyowa Kirin, Inc.
Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of GNTbm-38 in adult patients with advanced solid tumors and R/R PTCL.
- Trial name
- NCT07842445
- Testing
- GNTbm-38
- Volunteers
- 70 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Peripheral T Cells Lymphoma (PTCL)
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
This is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to…
- Trial name
- PALT1 (NCT06495723)
- Testing
- LIS1
- Where
- 8 sites in France, Italy
- Volunteers
- 54 people
- Sponsor
- Xenothera SAS
Peripheral T-cell Lymphomas (PTCL), PTCL-NOS
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose…
- Conditions
- Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), ALK- Anaplastic Large Cell Lymphoma (ALCL)
- Trial name
- FIL_PTCL13 (NCT02223208)
- Testing
- Ro-CHOEP-21 (PHASE I), Ro-CHOEP-21 (PHASE II)
- Where
- 27 sites in Italy
- Volunteers
- 89 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C7R) and a chimeric antigen receptor (CAR) for CD30…
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma, ALK-Positive
- Trial name
- ANCILE-30 (NCT07729397)
- Testing
- Autologous C7R.CD30-CAR-EBVSTs
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The Methodist Hospital Research Institute
Peripheral T-cell Lymphoma (PTCL)
New Genotype-guided Treatment in Newly Diagnosed PTCL
This is a phase I/II study evaluate the safety and efficacy targeted agents in combination with standard CHOP in new genotypic subtypes in treatment naive peripheral T-cell lymphoma. Phase I is to confirm RP2D of targeted agent.
- Trial name
- G08 (NCT07706959)
- Testing
- Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Ruijin Hospital
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Expanded Access to Tipifarnib
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
- Trial name
- Kuraoncology (NCT04809233)
- Testing
- Tipifarnib
- Sponsor
- Kura Oncology, Inc.
PTCL, T Cell Lymphoma
A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.
A multi-center, prospective, registry study to analyze the clinical characteristics and prognosis of different molecular subtypes of peripheral T-cell lymphoma.
- Trial name
- EXCELLENT (NCT07657572)
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. These T-cell neoplasms account for approximately 10-15% of all lymphomas.
- Conditions
- Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
- Trial name
- NCT07535762
- Testing
- Aclarubicin, Cyclophosphamide, Vincristine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Phase 1 (dose-escalation part): Investigate the tolerability and safety of ASTX660 in patients with r/r PTCL and r/r CTCL and determine the recommended dose (RD) for the Phase 2.
- Trial name
- NCT04362007
- Testing
- ASTX660
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Peripheral T Cells Lymphoma (PTCL)
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas.
- Trial name
- PlaTform (NCT07018752)
- Testing
- roginolisib, golcadomide, azacitidine
- Where
- 20 sites in France
- Volunteers
- 49 people
- Sponsor
- The Lymphoma Academic Research Organisation
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Primary Objective To evaluate the preliminary efficacy of Purinostat Mesylate for Injection in patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Secondary Objectives 1.
- Trial name
- NCT06485219
- Testing
- 11.2 mg/m2 Purinostat Mesylate, 15 mg/m2 Purinostat Mesylate
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
- Trial name
- NCT06909877
- Testing
- HH2853 Tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Peripheral T Cells Lymphoma (PTCL)
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
This clinical trial is a Phase II study investigating the effectiveness and safety of a three-drug combination-Zeprumetostat, Azacitidine, and Mitoxantrone Hydrochloride Liposome-in adults with relapsed or refractory peripheral…
- Trial name
- NCT07372352
- Testing
- Zeprumetostat, Azacitidine (AZA), Mitoxantrone Hydrochloride Liposome
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Peripheral T-cell Lymphomas (PTCL)
Golidocitinib Combined With GemOx in RR PTCL
The objective of this study is to evaluate the efficacy and safety of golidocitinib in combination with the GemOx regimen in r/r PTCL
- Trial name
- NCT07279584
- Testing
- golidocitinib, GEMOX
- Volunteers
- 31 people
- Sponsor
- Ruijin Hospital
NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL)
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
This study will test whether anti-EBV autologous TCR-T cell injection is safe and effective for patients with relapsed or refractory EBV-positive lymphoma who have HLA-A11:01.
- Conditions
- NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), DLBCL
- Trial name
- Anti-EBV TCR-T (NCT07162012)
- Testing
- EBV TCR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Peripheral T Cells Lymphoma (PTCL)
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of linperlisib combined with chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma
- Trial name
- NCT07139353
- Testing
- Linperlisib, Chidamide
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Peripheral T-cell Lymphoma (PTCL)
A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma
This real-world study aims to evaluate the safety and efficacy of golidocitinib-based treatment regimens in patients with peripheral T-cell lymphoma (PTCL), without intervention in the selection of therapeutic strategies.
- Trial name
- JOYCE (NCT06963632)
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital